on OXURION (EBR:OXUR)
Oxurion Launches Exagis eTMF Module to Enhance Clinical Trials
Oxurion, a biopharmaceutical company based in Leuven, Belgium, has introduced its electronic Trial Master File (eTMF) module, a step towards expanding its Exagis eClinical software platform. The new module is designed to improve efficiency, ease clinical trial operations, and ensure regulatory compliance.
Developed by Axiodis CRO, Oxurion's subsidiary, the Exagis platform reflects extensive real-world clinical operations. It caters to the needs of sponsors and research teams by integrating software development with clinical execution.
This launch marks progress in Oxurion's strategy to build a comprehensive eClinical platform. Future updates may include AI-assisted study design, adaptive randomization, and advanced analytics to enhance platform value and customer engagement.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all OXURION news